These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 18020621)

  • 41. Telomeres, telomerase and cancer: an endless search to target the ends.
    Satyanarayana A; Manns MP; Rudolph KL
    Cell Cycle; 2004 Sep; 3(9):1138-50. PubMed ID: 15467446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth.
    Lu R; Pal J; Buon L; Nanjappa P; Shi J; Fulciniti M; Tai YT; Guo L; Yu M; Gryaznov S; Munshi NC; Shammas MA
    Oncogene; 2014 Mar; 33(12):1495-505. PubMed ID: 23604115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting human telomerase by antisense oligonucleotides and ribozymes.
    Folini M; Pennati M; Zaffaroni N
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):605-12. PubMed ID: 12678727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Telomeres, telomerase and cancer: is the magic bullet real?
    Sharma HW; Maltese JY; Zhu X; Kaiser HE; Narayanan R
    Anticancer Res; 1996; 16(1):511-5. PubMed ID: 8615664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Telomere and telomerase as targets for anti-cancer drugs].
    Ide T
    Nihon Rinsho; 2004 Jul; 62(7):1271-6. PubMed ID: 15283143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Telomere maintenance mechanisms as a target for drug development.
    Bearss DJ; Hurley LH; Von Hoff DD
    Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Telomere and telomerase in human cancer].
    Hiyama K; Hiyama E; Ishioka S; Yamakido M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):196-201. PubMed ID: 9030230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors.
    Saraswati AP; Relitti N; Brindisi M; Gemma S; Zisterer D; Butini S; Campiani G
    Drug Discov Today; 2019 Jul; 24(7):1370-1388. PubMed ID: 31136800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy.
    Crees Z; Girard J; Rios Z; Botting GM; Harrington K; Shearrow C; Wojdyla L; Stone AL; Uppada SB; Devito JT; Puri N
    Curr Pharm Des; 2014; 20(41):6422-37. PubMed ID: 24975605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The role of alternative lengthening of telomeres mechanisms in carcinogenesis and prospects for using an anti-telomerase drugs in malignant tumors treatment].
    Grach AA
    Tsitologiia; 2011; 53(10):759-71. PubMed ID: 22232932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Telomeres and telomerase, new targets for anticancer chemotherapy].
    Riou JF; Morjani H; Trentesaux C
    Ann Pharm Fr; 2006 Mar; 64(2):97-105. PubMed ID: 16568010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
    Seimiya H; Muramatsu Y; Ohishi T; Tsuruo T
    Cancer Cell; 2005 Jan; 7(1):25-37. PubMed ID: 15652747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.
    Raymond E; Sun D; Izbicka E; Mangold G; Silvas E; Windle B; Sharma S; Soda H; Laurence R; Davidson K; Von Hoff DD
    Br J Cancer; 1999 Jul; 80(9):1332-41. PubMed ID: 10424733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term in vitro treatment with telomerase inhibitor MST-312 induces resistance by selecting long telomeres cells.
    Morais KDS; Arcanjo DDS; de Faria Lopes GP; da Silva GG; da Mota THA; Gabriel TR; Rabello Ramos DDA; Silva FP; de Oliveira DM
    Cell Biochem Funct; 2019 Jun; 37(4):273-280. PubMed ID: 31012504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in the molecular design of potential anticancer agents via targeting of human telomeric DNA.
    Maji B; Bhattacharya S
    Chem Commun (Camb); 2014 Jun; 50(49):6422-38. PubMed ID: 24695755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death.
    Herbert B; Pitts AE; Baker SI; Hamilton SE; Wright WE; Shay JW; Corey DR
    Proc Natl Acad Sci U S A; 1999 Dec; 96(25):14276-81. PubMed ID: 10588696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
    Kelland L
    Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oligonucleotides Targeting Telomeres and Telomerase in Cancer.
    Schrank Z; Khan N; Osude C; Singh S; Miller RJ; Merrick C; Mabel A; Kuckovic A; Puri N
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30189661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Telomerase: a target for cancer therapeutics.
    Shay JW; Wright WE
    Cancer Cell; 2002 Oct; 2(4):257-65. PubMed ID: 12398889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.